MR imaging of tumor microcirculation: promise for the new millennium
- PMID: 10581502
- DOI: 10.1002/(sici)1522-2586(199912)10:6<903::aid-jmri1>3.0.co;2-a
MR imaging of tumor microcirculation: promise for the new millennium
Abstract
Dynamic contrast-enhanced magnetic resonance imaging (DCE MRI) is a method of imaging the physiology of the microcirculation. A series of recent clinical studies have shown that DCE MRI can measure and predict tumor response to therapy. Recent advances in MR technology provide the enhanced spatial and temporal resolution that allow the application of this methodology in the management of cancer patients. The September issue of this journal provided a microcirculation section to update readers on this exciting and challenging topic. Evidence is mounting that DCE MRI-based measures correlate well with tumor angiogenesis. DCE MRI has already been shown in several types of tumors to correlate well with traditional outcome measures, such as histopathologic studies, and with survival. These new measures are sensitive to tumor physiology and to the pharmacokinetics of the contrast agent in individual tumors. Moreover, they can present anatomical images of tumor microcirculation at excellent spatial resolution. Several issues have emerged from recent international workshops that must be addressed to move this methodology into routine clinical practice. First, is complex modeling of DCE MRI really necessary to answer clinical questions reliably? Clinical research has shown that, for tumors such as bone sarcomas, reliable outcome measures of tumor response to chemotherapy can be extracted from DCE MRI by methods ranging from simple measures of enhancement to pharmacokinetic models. However, the use of similar methods to answer a different question-the differentiation of malignant from benign breast tumors-has yielded contradictory results. Thus, no simple, one-size-fits-all-tumors solution has yet been identified. Second, what is the most rational and reliable data collection procedure for the DCE MRI evaluation? Several groups have addressed population variations in some key variables, such as tumor T(1)0 (T(1) prior to contrast administration) and the arterial input function C(a)(t) for contrast agent, and how they influence the precision and accuracy of DCE MRI outcomes. However, despite these potential complications, clinical studies in this section show that some tumor types can be assessed by relatively simple dynamic measures and analyses. The clinical scenario and tumor type may well determine the required complexity of the DCE MRI exam procedure and its analysis. Finally, we suggest that a consensus on naming conventions (nomenclature) is needed to facilitate comparison and analysis of the results of studies conducted at different centers. J. Magn. Reson. Imaging 10:903-907, 1999.
Copyright 1999 Wiley-Liss, Inc.
Similar articles
-
Technical innovation in dynamic contrast-enhanced magnetic resonance imaging of musculoskeletal tumors: an MR angiographic sequence using a sparse k-space sampling strategy.Skeletal Radiol. 2013 Jul;42(7):993-1000. doi: 10.1007/s00256-013-1604-9. Epub 2013 Apr 5. Skeletal Radiol. 2013. PMID: 23558650
-
Three-dimensional contrast enhanced ultrasound score and dynamic contrast-enhanced magnetic resonance imaging score in evaluating breast tumor angiogenesis: correlation with biological factors.Eur J Radiol. 2014 Jul;83(7):1098-1105. doi: 10.1016/j.ejrad.2014.03.027. Epub 2014 Apr 12. Eur J Radiol. 2014. PMID: 24794865
-
Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma.Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):770s-776s. doi: 10.1158/1078-0432.CCR-06-1921. Clin Cancer Res. 2007. PMID: 17255308 Review.
-
Limitations of single slice dynamic contrast enhanced MR in pharmacokinetic modeling of bone sarcomas.Acta Radiol. 2009 Jun;50(5):512-20. doi: 10.1080/02841850902922761. Acta Radiol. 2009. PMID: 19431058
-
Dynamic contrast-enhanced MRI for oncology drug development.J Magn Reson Imaging. 2016 Aug;44(2):251-64. doi: 10.1002/jmri.25173. Epub 2016 Feb 8. J Magn Reson Imaging. 2016. PMID: 26854494 Review.
Cited by
-
Pharmacodynamic analysis of magnetic resonance imaging-monitored focused ultrasound-induced blood-brain barrier opening for drug delivery to brain tumors.Biomed Res Int. 2013;2013:627496. doi: 10.1155/2013/627496. Epub 2013 Mar 31. Biomed Res Int. 2013. PMID: 23607093 Free PMC article.
-
The biology underlying molecular imaging in oncology: from genome to anatome and back again.Clin Radiol. 2010 Jul;65(7):517-21. doi: 10.1016/j.crad.2010.04.005. Clin Radiol. 2010. PMID: 20541651 Free PMC article.
-
Perfusion-weighted magnetic resonance imaging of the brain: techniques and application in children.Eur Radiol. 2004 Jan;14(1):59-72. doi: 10.1007/s00330-003-1972-y. Epub 2003 Jun 25. Eur Radiol. 2004. PMID: 12827431 Review.
-
Assessment of neovascular permeability in a pancreatic tumor model using dynamic contrast-enhanced (DCE) MRI with contrast agents of different molecular weights.MAGMA. 2011 Aug;24(4):225-32. doi: 10.1007/s10334-011-0256-9. Epub 2011 May 13. MAGMA. 2011. PMID: 21567161
-
Dynamic Contrast Enhanced Magnetic Resonance Imaging in Oncology: Theory, Data Acquisition, Analysis, and Examples.Curr Med Imaging Rev. 2009 May 1;3(2):91-107. doi: 10.2174/157340507780619179. Curr Med Imaging Rev. 2009. PMID: 19829742 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous